Retrospective Cohort Study
Copyright ©The Author(s) 2017.
World J Radiol. Sep 28, 2017; 9(9): 350-358
Published online Sep 28, 2017. doi: 10.4329/wjr.v9.i9.350
Table 3 Characteristics of patients in whom elevated prostatic 18F-labelled fluorodeoxyglucose uptake was investigated
Age (yr)18F-FDG PET/CT indicationProstate SUVmaxPSA (ng/mL)Urology referral madeUrology outcome
68Adrenal nodule10.43YesMRI - no suspicious foci
77Lung nodule4.52.78YesBiopsy - high-grade PIN
67Non-Hodgkin lymphoma4.55.5YesMRI - suspicious foci
Biopsy - benign
68Colorectal cancer5.93.04YesPSA monitoring
58Colorectal cancer7.61.38YesPSA monitoring
64Non-Hodgkin lymphoma5.41.84YesPSA monitoring
58Non-Hodgkin lymphoma19.97.44YesPSA monitoring
81Cholangiocarcinoma10.318YesLost to follow up
75Hepatic metastases (colorectal primary)8-YesLost to follow up
61Colorectal cancer141.47No - PSA normal
55Paraneoplastic syndrome4.80.62No - PSA normal
61Non-Hodgkin lymphoma5.82.85No - PSA normal
68Gastrointestinal stromal tumour13.21.48No - PSA normal
71Hepatic metastases (colorectal primary)9.24.9No - palliative care
87Oesophageal cancer5.311.86No - palliative care
82Colorectal cancer15.43.85No - palliative care
35Hodgkin lymphoma11.83.04No - suspected prostatitis
71Oesophageal cancer7.34.58No - likely urethral uptake